Non-clinical safety evaluation of prophylactic mRNA vaccine:general principles and concerns
Zhongguo Yaolixue yu Dulixue Zazhi = Chinese Journal of Pharmacology and Toxicology
; 36(8):561, 2022.
Article
Dans Anglais
| ProQuest Central | ID: covidwho-2167921
ABSTRACT
Messenger RNA(mRNA) vaccine, with antigen-encoded mRNA packaged in delivery vehicles, performs its functions via antigen translation and specific immune response. mRNA vaccines have proven their protective effects and safety in the ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2). The World Health Organization issued guidelines specifically for prophylactic mRNA vaccines in 2021, which provide important guidance for non-clinical research on mRNA vaccines. Furthermore, some unusual adverse reactions, such as cerebrovascular disease, embolic stroke, transient cerebral ischemia, deep vein thrombosis, myocarditis(pericarditis) and allergic reactions, have been also found in clinical trials and applications of mRNA vaccines, which deserves attention in non-clinical studies.
Collection:
Bases de données des oragnisations internationales
Base de données:
ProQuest Central
Type d'étude:
Études expérimentales
/
Étude pronostique
Les sujets:
Vaccins
langue:
Anglais
Revue:
Zhongguo Yaolixue yu Dulixue Zazhi = Chinese Journal of Pharmacology and Toxicology
Année:
2022
Type de document:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS